and research. It would be a big step backwards and a tragedy for science in general to be affected by new constraints. This is likely to be a very difficult area to negotiate since reducing net immigration was a major reason for the Brexit vote. It is interesting to note that the arrival of Theresa May as Prime Minister brought about some immediate changes that impact the life sciences sec-tor. Encouragingly, the government has expressed openly a very high priority to research. The Office for Life Sciences (OLS) will remain a joint unit across the Department of Health (DH) and the newly formed Department for Business, Energy, and Industrial Strategy. 6 The Chair of the newly created UK Research and Innovation body, Sir John Kingman, was recently quoted as saying: ''The critical point for me is that the new Prime Minister has quite rightly called for a new industrial strategy posing the question what is the best way to formulate a new economic future for an independent UK outside the European Union and I think that great science, great research universities have a huge amount to contribute to that.'' With that vision in mind, there is clearly a new opportunity to draw up a cohesive strategy for the field of cell and gene therapy that runs from discovery science through to commercialization. The United Kingdom has a highly skilled workforce in the life sciences sector. This is likely to keep the United Kingdom attractive for investment. A positive signal that the United Kingdom may remain strong was the announcement from Glaxo SmithKline that they will further enhance their investment in the UK advanced manufacturing, principally because of the United Kingdom's available highly skilled workforce. 7 Much of the dissemination of research and impact is through open scientific discourse. Now more than ever, the cell and gene therapy field should come together to ensure a bilaterally positive outcome of Brexit. The European Society of Gene and Cell Therapy together with the British Society of Gene and Cell Therapy and many other individual member state societies must play a proactive role to ensure that the pillars of scientific collaboration and mobility across geographical Europe are maintained, and even enhanced.
There is more to all of this than Brexit, which has focused minds on relationships and political ideals within Europe. As a scientific community, there are no geographical boundaries. Few would disagree with the notion that the best science is conducted collaboratively. Aside from monetary resource, mobility for research, training, and healthcare is par-amount. The forthcoming negotiations are of critical importance for the development of gene and cell therapy. Any reduction in funding, scientific and clinical interactions, and joined-up regulatory systems will have a detrimental impact on development of these innovative new medicines for both the United Kingdom and the EU. Scientists throughout Europe should therefore press the case for continued pan-European collaboration post-Brexit.
